16063-89-1

Basic information

• Product Name: 3-amino-N-hydroxybenzamide
• CAS NO: 16063-89-1
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.1506
• Mol File: 16063-89-1.mol

Chemical Properties

• Density: 1.345g/cm³
• Refractive Index: 1.645
• CAS DataBase Reference: 3-amino-N-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-N-hydroxybenzamide(16063-89-1)
• EPA Substance Registry System: 3-amino-N-hydroxybenzamide(16063-89-1)

Safety Data

• Hazardous Substances Data: 16063-89-1(Hazardous Substances Data)

Upstream product

• 4518-10-9 Methyl 3-aminobenzoate 

Relevant articles and documents

Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease

Multitarget agents simultaneously trigger molecules in functionally complementary pathways, and are therefore considered to have potential in effectively treating Alzheimer's disease (AD), which has a complex pathogenetic mechanism. In this study, the HDAC inhibitor core is incorporated into the acetylcholine esterase (ACE) inhibitor acridine–derived moiety and resulted in compounds that exhibited higher class IIa HDAC (4, 5, 7, and 9)- and class IIb HDAC6-inhibiting activity when compared to the pan-HDAC inhibitor SAHA in clinical practice. One of these compounds, 11b, displayed greater selectivity toward HDAC6 than other isoform enzymes. In contrast, the activity of compound 6a was selective toward class IIa HDAC and HDAC6. These two compounds exhibited strong activity against Aβ-aggregation as well as significantly disrupted Aβ-oligomer. Additionally, 11b and 6a strongly inhibited AChE. These experimental findings demonstrate that compounds 11b and 6a are HDAC-Aβ-aggregation-AChE inhibitors. Notably, they can enhance neurite outgrowth, but with no significant neurotoxicity. Further biological evaluation revealed the various cellular effects of multitarget compounds 11b and 6a, which have the potential to treat AD.

Monohydroxamic acids and bridging dihydroxamic acids as chelators to ruthenium(iii) and as nitric oxide donors: Syntheses, speciation studies and nitric oxide releasing investigation

The synthesis and spectroscopic characterisation of novel mononuclear RuIII(edta)(hydroxamato) complexes of general formula [Ru(H 2edta)(monoha)] (where monoha = 3- or 4-NH2, 2-, 3- or 4-Cl and 3-Me-phenylhydroxamato), as well as the first example of a Ru III-N-aryl aromatic hydroxamate, [Ru(H2edta)(N-Me-bha)] ·H2O (N-Me-bha = N-methylbenzohydroxamato) are reported. Three dinuclear RuIII complexes with bridging dihydroxamato ligands of general formula [{Ru(H2edta)}2(μ-diha)] where diha = 2,6-pyridinedihydroxamato and 1,3- or 1,4-benzodihydroxamato, the first of their kind with RuIII, are also described. The speciation of all of these systems (with the exception of the Ru-1,4-benzodihydroxamic acid and Ru-N-methylbenzohydroxamic systems) in aqueous solution was investigated. We previously proposed that nitrosyl abstraction from hydroxamic acids by Ru III involves initial formation of RuIII-hydroxamates. Yet, until now, no data on the rate of nitric oxide (NO) release from hydroxamic acids has been published. We now describe a UV-VIS spectroscopic study, where we monitored the decrease in the ligand-to-metal charge-transfer band of a series of RuIII-monohydroxamates with time, with a view to gaining an insight into the NO-releasing properties of hydroxamic acids. The Royal Society of Chemistry.

Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners

Methods, compounds, and formulations are provided to reduce pigmentation in mammalian skin, comprising hydroxamic acid and its derivatives, and especially benzohydroxamic acid and its derivatives. The compounds preferably inhibit pigment synthesis in melanocytes through inhibition of melanocyte tyrosinase. The methods can be used for lightening skin, and for treating uneven skin complexions, which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically, and preferably as topical formulations.

Copper(II) complexes of isomeric aminophenylhydroxamic acids. A novel 'clam-like' dimeric metallacrown and polymeric helical structure containing interlinked unique copper(II) sites

The reaction of 3-aminophenylhydroxamic acid with CuSO4·5H2O in aqueous solution gives the novel helical polymer [Cu3(3-Apha)4(H2O)SO4] n·8H2O 1 the structure of which contains interlinked repeating units having three unique neutral, anionic and cationic copper(II) sites. In this complex the copper(II) sites are magnetically non-interacting. A similar reaction with 2-aminophenylhydroxamic acid gives the novel dimeric 'metallacrown' [Cu5(2-AphaH-1)4(μ-SO4)(H 2O)2]2·10H2O 2 which has a 'clam-like' structure showing strong antiferromagnetic behaviour. In contrast to the above ligands, 4-aminophenylhydroxamic acid gives the monomeric square planar complex Cu(4-Apha)2·H2O 3 which exhibits paramagnetic behaviour. Crystal structures of all three complexes are reported.

Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: Inhibition of ribonucleotide reductase and antitumor activity

Benzohydroxamic acids inhibit mammalian ribonucleotide reductase and exhibit antineoplastic activity in L1210 leukemic mice. Five new hydroxy- and amino-substituted benzohydroxamic acids (3,4- and 3,5-OH,3,4-NH2, 2,3,4-, and 3,4,5-OH) were prepared and tested along with 12 previously reported benzohydroxamic acids (BHA) for enzyme inhibition and antitumor activity. The most potent enzyme inhibitor in this series was 2,3,4-OH-BHA (ID50=3.5 μM), which is 140 times more potent than hydroxyurea, but its toxicity limited the antitumor activity to a 30% increase in life span of L1210 bearing mice at 125 (mg/kg) day ip for 8 days. The most effective antitumor agent in this series was 3,4-OH-BHA which prolonged the life span of L1210 bearing mice 103% at 600 (mg/kg)/day ip for 8 days.